Archive | Redefining Early Stage Investments (RESI) RSS feed for this section

RESI Partnering Week November Preliminary Agenda

30 Sep

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Registration is now open for RESI Partnering Week, November 16-18! Super early bird rates end next week, so check out our preliminary agenda below, featuring investor panels specific to life science and healthcare, as well as AI and age-tech applications. Sign up by Friday, October 8 to save $200 on registration!

Tuesday, November 16

11:00 AM EDT – Oncology Innovation Panel

The Search for New Approaches to Diagnosing & Treating Cancer

This panel is a discussion on topics relevant to investment in current innovations in the oncology space. Topics the panelists might consider discussing include:

  • The technologies/approaches that investors find the most compelling
  • Whether platform technologies or single assets are preferred for investment/partnerships
  • What criteria do investors use when assessing companies for their portfolio or pipeline

Panelists can discuss the industry-wide changes currently seen, including the rise of new therapeutic approaches (CAR-T, oncolytic viruses etc.), and how that is affecting the investing landscape.

12:00 PM EDT – Fireside Chat: The Future of Aging in Place

The Covid-19 global pandemic has highlighted the need for safe, accessible remote care, particularly for seniors and vulnerable populations, making aging in place no longer merely a preference for older adults, but also a priority for healthcare providers. Hear the latest industry news on how home-based care has improved in the past couple years and the miles still to go.

2:00 PM EDT – AI-Assisted Remote Care & Chronic Disease Management Panel

Mobile and Home-Based Patient Support

Millions living with chronic disease are often tasked with being their own caregivers in addition to being patients. AI-assisted tech can ease some of the burden of day-to-day management, enabling users to live happier and healthier lives without compromising care. Learn from investors working with early-stage tech to tackle the challenges, risks, and the potential of the latest innovation connecting patients with their care more efficiently.

3:00 PM EDT – Medtech Strategics Panel

Large Corporations Seeking External Innovation in Medtech

In the medical technology sector, major corporations are increasingly looking to external startups and inventors for innovative new technologies. In addition to traditional M&A, these major strategic players are exploring innovative strategies to partner with early-stage startups, and our speakers will explore topics such as:

  • How do major corporations find new device technologies that are fit their pipelines?
  • What can an early-stage startup do to find the right partner?
  • How do partnerships work, and what conditions might a major partner have?
  • What kind of technical and commercial validation will be required to secure a partnership?

The panelists will explore these topics with reference to the technology areas that they are looking at for their future pipelines.

4:00 PM EDT – Tales from the Road: Age-Tech Innovators on Their Fundraising Journey

Age-tech entrepreneurs are pounding the pavement, seeking funding to enable seniors to live longer, healthier lives. Learn the strategies they’ve implemented to stand out to investors, book meetings, make deals, and work effectively with investors and strategic partners.

5:00 PM EDT – Angels & Family Offices Panel

How Do Family Offices & Angels View Seed & Series A Rounds?

Angel investors are a mainstay in the earliest financing rounds, and many consider Family Offices as the holy grail of investors. These groups share many similarities and can work in synergy to help their portfolio companies advance. This panel will cover topics such as:

  • What are the similarities and differences between Angels and Family Offices?
  • What are the benefits of working with each group?
  • How does investing personal money change the way Angels and Family Offices act from the traditional VC?

A startup looks to different types of investors when fundraising and understanding the fundamental differences between groups can improve the success of their approach. Angels and Family Offices frequently invest early on and can shape the way a company develops. Panelists will discuss how best to approach them and engage their interest.

Wednesday, November 17

11:00 AM EDT – am Cognitive Care Panel

Advancing Treatments in Matters of the Mind

Cognitive decline in the aging population includes several signs and symptoms. Studies show that most experience a slowing in cognitive skills around the age of 60. These conditions can range in severity, from decreased processing speed, loss of memory, social withdrawal and increased anxiety. Cognitive decline feels vast and inevitable but learning from investors in this sector on the ideas and advances they’re seeing in the industry, toward treatment options reveals exciting opportunities to improve this side effect of aging.

12:00 PM EDT – Fireside Chat: The CRO Impact on Drug Development

Clinical Research Organizations (CRO) are integral to the development of therapeutics, however, connecting with the right ones for an early-stage company’s needs isn’t always straightforward. Learn how successful companies are connecting with the right CROs for them and how they can optimize the relationship to advance drug development.

2:00 PM EDT – Investing in Precision Medicine Panel

Improving Outcomes through a Patient-Tailored Approach

This panel discusses current trends in precision medicine. Topics may include:

  • How investors assess precision medicine technologies and applications in diagnostics, drug discovery and treatment plans
  • Which indications investors believe are showing the most promise – genetic disorders, orphan diseases, oncology, etc.
  • Investing in individualized treatments (such as CAR-T) and the scalability challenges of autologous vs allogeneic/xenogeneic off-the-shelf treatments
  • The regulatory challenges some of these technologies face, whether to ensure individual privacy from genomics databanks or to prevent potential harmful side effects from therapeutics such as CRISPR technologies

Precision medicine has proven to produce more effective treatments in multiple indications by tailoring medical treatment to the individual and their disease. Additionally, early detection of disease has improved outcomes for many patients. Panelists will discuss where the field is heading and what unique challenges companies in this area will face.

3:00 PM EDT – Clinical & Research Data Panel

Engaging AI in Collection, Application, and Targeting Bias

AI technology has enabled countless technological breakthroughs in the healthcare arena, but one area in which it is still limited is through data. Like gas to a car, the right data is necessary for AI to truly help clinicians and patients. Investors focused on targeting this challenge through their early-stage deal flow meet to discuss these challenges and how they work with companies seeking to eliminate bias and error.

4:00 PM EDT – Tales from the Road: Biotech and Medtech Innovators on Their Fundraising Journey

The industry has quickly adapted to a “new normal” – entrepreneurs and investors meet virtually over digital platforms to discuss potential investment opportunities, and it is not uncommon to see entrepreneurs raise capital from investors they have never met before in person. That said, there is no doubt that the fundraising journey continues to be challenging for many. In this panel, you will be able to hear fellow entrepreneurs share their experiences, from successes to challenges.

This panel will discuss the following topics and more:

  • What are some of the greatest challenges entrepreneurs have faced, especially during the pandemic, and how were they overcome?
  • How did entrepreneurs identify investors that fit their technology?
  • What are some misconceptions entrepreneurs had about the early-stage investment landscape?

Furthermore, entrepreneurs will share unique tips and insights they have gained from their fundraising experiences, and how others can work their way towards a more successful campaign.

Thursday, November 18

11:00 AM EDT – Digital Health Panel

Leveraging Software to Lower Costs and Improve the Quality of Care

This panel focuses on investing in innovative digital health products that bring new efficiencies to the healthcare system, change how care is delivered or managed, and how patients are involved in their own care. Panelists will explore topics related to investing in digital health, including:

  • In what kinds of digital health technologies are they interested in investing?
  • What metrics and evidence do you look for in a digital health startup?
  • How can an early stage digital health company demonstrate the value of their products?
  • What are the main challenges for startups raising capital in this space?

The moderator and panelists will discuss this rapidly evolving field of healthcare investment, and will introduce the audience to the key fundraising opportunities and challenges facing digital health entrepreneurs today.

12:00 PM EDT – Fireside Chat: AI-Assisted Imaging in Diagnosis

Few areas of healthcare show more promise through AI applications than radiology. Through AI-enabled imaging, clinicians are able to work harder and smarter, as well as provide more accurate and detailed information crucial to patient care. Learn about the future of AI in pathology and imaging and where the industry is headed next.

2:00 PM EDT – Women in Age-Tech

Investing in Strategy and Success

Women remain the majority of caregivers in 2021 and the difference between male and female caregivers providing more hours of unpaid care is much greater. Hear from healthcare investors working with age-tech entrepreneurs to bridge the care and equity gap in senior care.

3:00 PM EDT – Impact Investors Panel

Life Science Investors Looking for More Than Financial Returns

This panel features four speakers and a moderator from firms that make equity investments into early-stage companies and organizations with the intent to generate a positive social or environmental impact alongside a financial return. Some of these firms focus on impacting a specific patient population, whereas others have broader goals in creating an impact for their local region, or the world. Topics may include:

  • What is impact investing?
  • How is the investment mandate affected by the impact goal? • How do investors measure and increase the impact of their capital?
  • How should startups approach impact investors for fundraising, and what criteria do they use to evaluate opportunities?
  • What separates an impact investor from a traditional VC?

Panelists will discuss how impact investors provide capital to address challenges in life sciences and healthcare sectors worldwide. While impact investing market is a relatively new trend, panelists will also discuss how companies can successfully fundraise from impact investors and the best way to develop a relationship with relevant investors.

4:00 PM EDT – Tales from the Road: AI Innovators on Their Fundraising Journey

Hear from fundraising entrepreneurs on their processes researching, pitching, and working with investors. AI technology has incredible potential in healthcare, but also raises unique challenges. Hear from founders on how AI fits into their story and solutions, and how they sourced the right investors for them.


Stories from the Innovator’s Pitch Challenge

30 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN


Since going digital in 2020, RESI conferences have been able to grow and meet the unique needs of virtual partnering in many ways, but few more exciting than the Innovator’s Pitch Challenge (IPC). The IPC is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. Participating companies pay registration and a $500 pitching fee to host their company materials on the Live Agenda and participate in the live pitch session.

Applications are due October 22, but those who apply by October 8 save an additional $200 with super early bird registration rates. Hear from past participants about their experiences pitching at RESI conferences and how their experiences contributed to their global fundraising efforts.


Scrappy, Strategic, and Starting Million-Dollar Conversations: The Sonavex Story

30 Sep

By Rory McCann, Marketing Manager & Conference Producer, LSN

Sonavex makes ultrasound accessible for non-sonographers through its technologies designed to improve imaging and detect issues. Their work is meant to create better clinician experience and better patient outcomes. In a conversation with Sonavex CEO, David Narrow, it’s clear that there’s so much more that goes into early-stage success than a great idea. It takes strategy and understanding how to use the tools available to you. One such tool Sonavex has used is the Redefining Early Stage Investment (RESI) conference series. Check out a recent interview to learn more about the Sonavex story and how the team made RESI work for them.

RESI Partnering Week, November 16-18 registration is open! Sign up today and save $200 on super early bird rates.



Registration for RESI Partnering Week November is Open!

23 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN


Thanks to the support and enthusiasm from the RESI community, another week of early-stage life science and healthcare partnering and innovation is in the books! We are excited to announce our last event of the year, RESI Partnering Week November, which will be a robust 3-day partnering conference, November 16-18.

Registration is now open featuring Super Early Bird rates until Friday, October 8. Innovator’s Pitch Challenge (IPC) applications are also open, giving companies a platform to present their technology to hundreds of RESI attendees. If your early-stage company is fundraising, you do not want to miss out on these discounted rates and unique presentation opportunities.


Looking for more ways to get involved? Check out sponsorship offerings and learn more about how you can boost your exposure to the RESI network and optimize your experience and connections!


RESI Longevity Innovator’s Pitch Challenge Winners

23 Sep

By Caitlin Dolegowski, Marketing Specialist, LSN

Last week, early-stage companies with a focus on conditions of aging were given the opportunity to pitch live at the digital RESI Longevity conference to relevant investor judges and industry experts as part of the Innovator’s Pitch Challenge (IPC). We were thrilled to host 15 pitching companies! The companies were divided into three pitching sessions – Medical Devices, Diagnostics & Therapeutics, and Digital Health. Congratulations to our RESI Longevity Innovator’s Pitch Challenge Winners! As the companies with the most votes, each will receive complimentary tickets to future RESI conferences to continue their fundraising efforts. Thank you to all our IPC finalists for providing great pitches and to our judges who came prepared with excellent questions. We look forward to future opportunities to highlight early-stage companies and gain valuable insight into what investors are considering.

Session 1 (Medical Devices) Winner


Alertgy has developed DeepGluco, a wearable noninvasive continuous glucose monitor and alert system which captures the dielectric spectrum of a user that can be used to measure glucose and other important compounds in the body. This will allow people a means to prevent becoming diabetic and increase their life span even with diabetes by giving them a means to better manage their lifestyle through instantaneous biometric feedback.

Session 2 (Diagnostics & Therapeutics) Winner


Praetego is biopharma company developing first-in-class Advanced Glycation End-product (AGE) inhibitors able to deter AGE formation at the initiation of pathology. Through this novel and proprietary small molecule technology, Praetego’s candidates are designed to slow or prevent diseases driven by oxidative stress. This includes the highly burdensome diseases of Neurodegeneration/Alzheimer’s, Diabetic Microvascular Disease, and Cardiovascular Disease.

Praetego’s AGE inhibitor platform technology applies to the chronic conditions of aging.
Praetego’s management team are drivers of successful drug development programs across therapeutic areas and regulatory pathways. The scientific leadership has spent 3 decades studying AGE inhibitors. A robust and growing patent estate protects this proprietary technology. Praetego is raising capital to reach clinical trials in 2022.

Session 3 (Digital Health) Winner

Embrace Prevention Care

We provide Personal Prevention Care to older adults with heart failure and other chronic conditions to improve health and reduce preventable hospital stays. We extend physicians’ reach into the home to help patients and caregivers take actions that achieve the goals that matter most while reducing the cost of care.

Our local nurse practitioners have weekly telehealth interactions with patients and build trusting relationships to help them take daily actions to implement care plans developed with their physicians. Our geriatric pharmacy ensures patients take the right meds with monthly deliveries in dose-time adherence packages. We empower caregivers to effectively help patients achieve their goals and coordinate actions with the entire care team. Our personalized, integrated care is reimbursed by Medicare.

Interested in joining the RESI November IPC? Apply today and save on super early bird rates! Applications are accepted on a rolling basis, so get started today!


RESI AI Innovator’s Pitch Challenge Winners

23 Sep

By Rory McCann, Marketing Manager & Conference Producer, LSN

Last week’s digital RESI AI conference connected early-stage AI startups with the investors, service providers, and strategic partners founders are looking for. The conference featured insightful panels, educational workshops, fit-focused partnering, and opportunities for fundraising entrepreneurs to pitch directly to a panel of investors, such as the Innovator’s Pitch Challenge (IPC).

Innovator’s Pitch Challenge winners were selected by attendees for the best pitch. Each company submitted marketing materials and a pitch video to their dedicated webpage, available to view by all attendees and judges. The live session included elevator pitches and time for Q&A with the judges and audience.

Congratulations to our IPC winners! Click the logos to learn more about each company:

Session 1 (Devices and Therapeutics) Winner


NeoPrediX develops decision support tools with maternal, neonatal and perinatal screening platforms to evaluate, optimize and personalize medical strategies in pediatrics. We utilize intelligent algorithms and digital health solutions for neonatal and perinatal care based on deep medical data and science, developed by experienced scientists, pediatricians, and neonatologists.

Session 2 (R&D/Manufacturing Services and Digital Health) Winner


SingularityAI builds an AI-driven medical image and data analytics platform of cloud software and smart devices with data privacy preserving technologies, to make AI-driven insights a broad reality for medical innovation.

Interested in joining the RESI November IPC? Apply today and save on super early bird rates! Applications are accepted on a rolling basis, so get started today!


Hot AI Mandate: US-based VC Invests in Software-based Companies with AI/ML Components in All Sectors

21 Sep

A venture capital firm based in Denver, Colorado and Dallas, Texas invests in companies of all sectors that have some AI/ML component. Within healthcare, the firm invests in revenue-generating companies. The firm will not invest in any company that requires FDA approval. The firm is currently investing out of their second $30M, with a third, $100M, to come soon. The firm invests primarily in the US, but reserves about 30% of their fund for investments in India. The firm invests in Series A and later companies, and will invest $0.5-2M per company.

The firm does not invest in therapeutics or medical devices, anything that requires FDA approval. The firm primarily invests in software-based companies, as long as the technology has an AI/ML component. This could include enterprise software, diagnostic image analysis or drug discovery platforms, as long as the therapeutics are then out-licensed, and not developed in house.

The firm can lead or co-invest, and will take a board or observer seat for larger check sizes. The firm is an active investor, and looks for management teams that are open to suggestion and are willing to benefit from the expertise of the firm and their network. The firm looks for companies that have at least $1M in ARR.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: